Effect of antiviral chemoprophylaxis on adverse clinical outcomes associated with cytomegalovirus after liver transplantation

Mayo Clinic Proceedings

Volumn 81, Issue 8, 2006, Pages 1029-1033

  Hellinger, Walter C ^a   Bonatti, Hugo ^a   Machicao, Victor I ^a,c   Yao, Joseph D ^b   Brumble, Lisa M ^a   Alvarez, Salvador ^a   Weigand, Stephen D ^b   Dickson, Rolland C ^a   Harnois, Denise M ^a   Spivey, James R ^a,d   Stapelfeldt, Wolf H ^a   Hughes, Christopher B ^a   Nguyen, Justin H ^a   Steers, Jeffery L ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d EMORY CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DEATH; DRUG EFFICACY; FEMALE; HUMAN; INFECTION PREVENTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; POSTOPERATIVE INFECTION; RECIPIENT; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

EID: 33746824548     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.8.1029     Document Type: Article

References (18)

1. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG, Boston Center for Liver Transplantation CMVIG Study Group. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann Intern Med. 1997;126:275-279.
2. Falagas ME, Paya C, Ruthazer R, et al. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation. 1998;66:1020-1028.
3. Rosen HR, Corless CL, Rabkin J, Chou S. Association of cytomegalovirus genotype with graft rejection after liver transplantation. Transplantation. 1998;66:1627-1631.
4. Falagas ME, Snydman DR, Griffith J, Werner BG, Boston Center for Liver Transplantation CMVIG Study Group. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Clin Infect Dis. 1996;23:468-474.
5. Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis [published correction appears in J Hepatol. 1993;19:325]. J Hepatol. 1993;18:185-195.
6. van den Berg AP, Klompmaker IJ, Haagsma EB, et al. Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transplant. 1996;10:224-231.
7. George MJ, Snydman DR, Werner BG, et al, Boston Center for Liver Transplantation CMVIG-Study Group. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med. 1997;103:106-113.
8. Kim WR, Badley AD, Wiesner RH, et al. The economic impact of cytomegalovirus infection after liver transplantation. Transplantation. 2000;69:357-361.
9. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients [published correction appears in Lancet. 1998;351:454]. Lancet. 1997;350:1729-1733.
10. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988 [published correction appears in Am J Infect Control 1988;16:177]. Am J Infect Control 1988;16:128-140.
11. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992;13:606-608.
12. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-1097.
13. Patel R, Klein DW, Espy MJ, et al. Optimization of detection of cytomegalovirus viremia in transplantation recipients by shell vial assay. J Clin Microbiol. 1995;33:2984-2986.
14. Madalosso C, de Souza NF Jr, Ilstrup DM, Wiesner RH, Krom RA. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation. 1998;66:294-297.
15. Singh N, Wannstedt C, Keyes L, Wagener MM, Gayowski T, Cacciarelli TV. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatits C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation. 2005;79:1428-1434.
16. Munoz-Price LS, Slifkin M, Ruthazer R, et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis. 2004 Nov 1;39:1293-1299. Epub 2004 Oct 11.
17. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:928-936.
18. Luckraz H, Charman SC, Wreghitt T, Wallwork J, Parameshwar J, Large SR. Does cytomegalovirus status influence acute and chronic rejection in heart transplantation during the ganciclovir prophylaxis era? J Heart Lung Transplant. 2003;22:1023-1027.